Fewer renal complications seen with tirzepatide versus insulin glargine in adults with T2D and increased cardiovascular risk
A study conducted in Taiwan is the first to show that hyperuricemia is as risky as diabetes in contributing to ESKD and death risk in patients with stage 3 to 5 CKD.
Study findings suggest the nephroprotective effects of both drug classes are complementary.
Study findings highlight an “unmet need” for newer therapies.
Investigators focused on the prognostic value of the uremic solutes asymmetric dimethylarginine, symmetric dimethylarginine, and trimethylamine-N-oxide.
Mendelian randomization study shows causal association between higher body mass index and increased risk for diabetic nephropathy
Diabetes is a possible risk factor for major bleeding complications after percutaneous renal biopsy, according to investigators.
Findings reported for subcutaneous treatment in overweight, obese adults also using diet, physical activity
Affordability of SGLT2i may contribute to the low prescription rate in CKD.
Atrasentan lowers the risk for a composite of kidney failure, doubling of serum creatinine, or kidney death consistently across subgroups of urinary albumin-creatinine ratio and estimated glomerular filtration rate.